Literature DB >> 10708588

Cancer cells responsible for humoral hypercalcemia express mRNA encoding a secreted form of ODF/TRANCE that induces osteoclast formation.

M Nagai1, S Kyakumoto, N Sato.   

Abstract

A novel cDNA encoding a secreted form of osteoclast differentiation factor/tumor necrosis factor-related activation-induced cytokine (sODF/TRANCE, GenBank Accession No. AB037599) was sequenced from 5' RACE cDNA clones of squamous cell carcinoma cell lines, SCC-4 and T3M-1 Cl.2, of which parental malignant tissues had caused severe humoral hypercalcemia. The sODF/TRANCE cDNA was composed of unknown 5' end sequence followed by the 100% identical sequence of the ODF/TRANCE extracellular domain-coding region. The longest open reading frame (ORF) of the novel cDNA completely matched the 3' end of the ORF of the ODF/TRANCE cDNA encoding C-terminal amino acid residues (74-318) in the extracellular region. The corresponding protein that reacted with the antibody specific for the extracellular domain of ODF/TRANCE was detected in the culture media conditioned by the cancer cells. Furthermore, human promyeloblastic leukemia cells, HL60, differentiated into osteoclast-like cells (OCLs) when cultured in the media conditioned by SCC-4 and T3M-1 Cl. 2 cells. The differentiation of HL60 cells into OCLs was inhibited by the anti-ODF/TRANCE antibody. These results strongly suggest that sODF/TRANCE plays an important role in enhanced bone-resorption in humoral hypercalcemia of malignancy. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10708588     DOI: 10.1006/bbrc.2000.2314

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  13 in total

1.  Osteolysis and cancer.

Authors:  D Goltzman
Journal:  J Clin Invest       Date:  2001-05       Impact factor: 14.808

2.  Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone.

Authors:  J Zhang; J Dai; Y Qi; D L Lin; P Smith; C Strayhorn; A Mizokami; Z Fu; J Westman; E T Keller
Journal:  J Clin Invest       Date:  2001-05       Impact factor: 14.808

Review 3.  Bone destruction in arthritis.

Authors:  E M Gravallese
Journal:  Ann Rheum Dis       Date:  2002-11       Impact factor: 19.103

Review 4.  Control of RANKL gene expression.

Authors:  Charles A O'Brien
Journal:  Bone       Date:  2009-08-27       Impact factor: 4.398

5.  Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis.

Authors:  Eva Grimaud; Luc Soubigou; Séverine Couillaud; Patrick Coipeau; Anne Moreau; Norbert Passuti; François Gouin; Françoise Redini; Dominique Heymann
Journal:  Am J Pathol       Date:  2003-11       Impact factor: 4.307

6.  Reduction of urinary levels of pyridinoline and deoxypyridinoline and serum levels of soluble receptor activator of NF-kappaB ligand by etanercept in patients with rheumatoid arthritis.

Authors:  Kageyama Yasunori; Takahashi Masaaki; Nagafusa Tetsuyuki; Kobayashi Hayato; Nagano Akira
Journal:  Clin Rheumatol       Date:  2008-03-13       Impact factor: 2.980

7.  Oral squamous carcinoma cells secrete RANKL directly supporting osteolytic bone loss.

Authors:  Xiaoyi Zhang; Carlos Rossa Junior; Min Liu; Fei Li; Nisha J D'Silva; Keith L Kirkwood
Journal:  Oral Oncol       Date:  2012-09-16       Impact factor: 5.337

8.  Osteoprotegerin in bone metastases: mathematical solution to the puzzle.

Authors:  Marc D Ryser; Yiding Qu; Svetlana V Komarova
Journal:  PLoS Comput Biol       Date:  2012-10-18       Impact factor: 4.475

9.  Activated human T cells express alternative mRNA transcripts encoding a secreted form of RANKL.

Authors:  N C Walsh; K A Alexander; C A Manning; S Karmakar; S K Karmakar; J F Wang; C M Weyand; A R Pettit; E M Gravallese
Journal:  Genes Immun       Date:  2013-05-23       Impact factor: 2.676

10.  The role of TNF-α and TNF superfamily members in the pathogenesis of calcific aortic valvular disease.

Authors:  Antonella Galeone; Domenico Paparella; Silvia Colucci; Maria Grano; Giacomina Brunetti
Journal:  ScientificWorldJournal       Date:  2013-11-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.